GERN - Geron Corporation
1.56 -0.00 (-0.01%)
Pre-Market: 8:07AM EST
| Previous Close | 1.4700 |
| Open | 1.4800 |
| Bid | 1.53 x 800 |
| Ask | 1.56 x 4000 |
| Day's Range | 1.4200 - 1.5900 |
| 52 Week Range | 0.9500 - 6.9900 |
| Volume | 4,250 |
| Avg. Volume | 3,353,324 |
| Market Cap | 290.703M |
| Beta (3Y Monthly) | 2.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.16 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.63 |
- Motley Fool•7 days ago
Why Geron Stock Briefly Spiked Today
This morning's move followed an upgrade by BTIG.
- GlobeNewswire•12 days ago
Analysis: Positioning to Benefit within National Oilwell Varco, Centene, Paylocity Holding, NorthStar Realty Europe, Geron, and NACCO Industries — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•14 days ago
Are Options Traders Betting on a Big Move in Geron (GERN) Stock?
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
- ACCESSWIRE•15 days ago
Biotech Stocks to Watch
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...
- Simply Wall St.•16 days ago
How Much is Geron Corporation’s (NASDAQ:GERN) CEO Getting Paid?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2011 Chip Scarlett was appointed CEO Read More...
- GlobeNewswire•20 days ago
Geron Announces Expansion of Leadership Team with Appointment of Chief Medical Officer
Geron Corporation (GERN) today announced an expansion of its leadership team with the appointment of a new chief medical officer to support the Company’s clinical drug development efforts in hematology-oncology. “As we transition to a late-stage development company, we are very pleased to welcome Dr. Aleksandra Rizo to Geron as Chief Medical Officer,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
- ACCESSWIRE•20 days ago
4 Biotech Stocks Making Moves On Thursday (1/31/19)
Premier Health Group (OTC:PHGRF) (CSE:PHGI), SCYNEXIS Inc (SCYX), Geron Corporation (GERN), and Fortress Biotech Inc (FBIO) represent four biotech companies creating new treatment technologies aimed to ensure that patients get the therapies best suited to their needs. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this week that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
- ACCESSWIRE•20 days ago
Biotech Stocks on the Rise
HENDERSON, NV / ACCESSWIRE / January 31, 2019 / With the IBB getting set to cap off its most bullish month in a while, the biotech industry could be in store for a major renaissance in 2019. Below are ...
- ACCESSWIRE•28 days ago
Best Ways to Play Biotech Rally
HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of ...
- GlobeNewswire•last month
Geron Appoints Vice President, Pharmacovigilance and Drug Safety
Geron Corporation (GERN) today announced the hiring of the first of several key leadership positions as it rebuilds the in-house development team to support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019. Israel Gutierrez, M.D., has joined the Company as Vice President, Pharmacovigilance and Drug Safety, as of January 16, 2019. Dr. Gutierrez will lead and direct the oversight of clinical drug safety risk management and compliance at Geron and will be responsible for product safety-related recommendations and decisions.
- Motley Fool•last month
Why Geron Stock Dropped 44% in 2018
Johnson & Johnson's decision to hand back imetelstat's rights caused Geron's share price to crumble last year.
- GlobeNewswire•2 months ago
Geron Announces New Board Leadership Structure
For personal reasons, effective December 26, 2018, Hoyoung Huh, M.D., Ph.D., has resigned from the Board, including his roles as Chairman of the Board and as a member of the Nominating and Corporate Governance Committee. Dr. Huh has served as Chairman of the Board since September 2011, and as a member of the Board since May 2010.
- ACCESSWIRE•2 months ago
Biotech Breakout Candidates
HENDERSON, NV / ACCESSWIRE / December 24, 2018 / It’s been a busy week for biotech, here are a few companies in the news you should start researching. Today we are highlighting: Delcath Systems, Inc. (DCTH), ...
- Motley Fool•2 months ago
Here Are Biotech’s Big Pipeline Disappointments in 2018
A number of companies suffered setbacks this year.
- Motley Fool•2 months ago
Top 10 Healthcare Stories of 2018
New drugs, trial flops, M&A, and a little bit of everything else that happened in healthcare in 2018.
- Simply Wall St.•3 months ago
Is Geron Corporation (NASDAQ:GERN) A Financially Sound Company?
Geron Corporation (NASDAQ:GERN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is GERN will Read More...
- GlobeNewswire•3 months ago
Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
Geron Corporation (GERN) today announced that results from IMbark, a Phase 2 clinical trial of imetelstat treatment in Intermediate-2 or High-risk myelofibrosis (MF) patients who are relapsed or refractory to a Janus Kinase (JAK) inhibitor, were presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The oral presentation was made on December 3, 2018 by John Mascarenhas, M.D., Associate Professor of Medicine in the Myeloproliferative Disorders Program of the Tisch Cancer Institute, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, and an IMbark clinical investigator.
- Benzinga•3 months ago
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...
- Zacks•3 months ago
Geron (GERN) Down 13% Since Last Earnings Report: Can It Rebound?
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•3 months ago
Geron to Host Analyst and Investor Event on December 10, 2018
Geron Corporation (GERN) today announced that the Company’s analyst and investor event will take place in New York, N.Y., on Monday, December 10, 2018. Management will be joined by clinical investigators from both IMerge and IMbark who will reprise oral presentations from the 60th American Society of Hematology (ASH) Annual Meeting occurring in early December, as well as discuss the unmet medical need in hematologic myeloid malignancies. Azra Raza, M.D., Chan Soon-Shiong Professor of Medicine and Director of the MDS Center in New York, will review data from Part 1 of the ongoing Phase 2/3 IMerge clinical trial of the telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes, including more mature efficacy and safety data from the combined initial and expansion cohorts presented at ASH.
- GlobeNewswire•3 months ago
Research Report Identifies Cheniere Energy Partners, LP, Arena Pharmaceuticals, Geron, Keysight Technologies, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, and Casella Waste with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•3 months ago
Healthcare Stocks with Turnaround Potential
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of GERN earnings conference call or presentation 1-Nov-18 8:30pm GMT
Q3 2018 Geron Corp Earnings Call
